6. パーキンソン病 Parkinson disease Clinical trials / Disease details

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

5 trials found

diseases per page:

Showing 1 to 5 of 5 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03575195 (ClinicalTrials.gov)	July 15, 2019	21/6/2018	Microbiota Intervention to Change the Response of Parkinson's Disease	Microbiota Intervention to Change the Response of Parkinson's Disease	Parkinson Disease	Drug: Rifaximin;Other: Placebo	University of California, San Francisco	Nova Southeastern University;Gateway Institute for Brain Research	Recruiting	30 Years	N/A	All	86	Phase 1/Phase 2	United States
2	NCT03958708 (ClinicalTrials.gov)	May 13, 2019	14/5/2019	Modulation of Gut Microbiota by Rifaximin in PD Patients	Modulation of Gut Microbiota by Rifaximin in PD Patients	Parkinson Disease;Inflammation	Drug: Rifaximin 550 MG	Taipei Medical University Shuang Ho Hospital	NULL	Recruiting	45 Years	70 Years	All	20	Phase 1/Phase 2	Taiwan
3	NCT04730245 (ClinicalTrials.gov)	June 1, 2018	25/1/2021	Microbiota Modification for the Treatment of Motor Complication of Parkinson´s Disease	Targeting Gut Microbiota for Motor Complications in Parkinson´s Disease	Parkinson's Disease Aggravated	Drug: sodium phosphate enema, oral rifaximin and polyethylene glycol	Torre Médica Santé	NULL	Completed	18 Years	N/A	All	14	Phase 1	Mexico
4	NCT02470780 (ClinicalTrials.gov)	December 2015	4/6/2015	Treating Bacterial Overgrowth in Parkinson's Disease	Treating Bacterial Overgrowth in Parkinson's Disease	Parkinson's Disease;Small Intestinal Bacterial Overgrowth	Drug: Rifaximin;Drug: Placebo	University of Cincinnati	NULL	Completed	18 Years	N/A	All	24	Phase 2/Phase 3	United States
5	NCT01662791 (ClinicalTrials.gov)	September 2012	7/8/2012	Weight Loss in Parkinson's Disease and Role of Small Bowel Bacterial Overgrowth	Weight Loss in Parkinson's Disease and the Potential Role of Small Bowel Bacterial Overgrowth	Parkinson's Disease	Drug: Rifaximin	Mayo Clinic	NULL	Completed	18 Years	N/A	All	49	Phase 3	United States

First Previous1Next Last